From Name:
From Email:
To Name:
To Email:

Optional Message:


Risk prediction, personalized medicine still in their infancy

from FierceHealthIT

While risk prediction and personalized therapies are advancing in some areas, there's much work to be done to make such efforts effective, according to an article in BMC Medicine. Daniel F. Hayes of the University of Michigan Comprehensive Cancer Center advocates for better industry oversight for tumor biomarker tests and the need to know whether a particular biomarker is significant clinically — whether to give or withhold a particular treatment more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063